Abstract
Acute promyelocytic leukemia (APL) is a special type of acute leukemia. The cure rate of APL has been significantly improved in the past decades due to the use of anthracyclines, all-trans retinoic acid and arsenic. Modern stratified treatment of APL further enhances the therapeutic efficacy and reduces the treatment-related toxicity. This article reviews the history of all-trans retinoic acid and arsenic into clinical application, and the characteristics of disease, treatment status of all-trans retinoic acid and arsenic, treatment mechanism and drug resistance mechanism in APL are introduced. Key words: Leukemia, promyelocytic, acute; Retinoic acid; Arsenical; Molecular mechanisms of pharmacological action; Drug-resistance mechanisms
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
